Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STP271G
- Development stage
- Preclinical
- Lead developer
- Sirnaomics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
STP271G is a preclinical-stage siRNA therapeutic developed by Sirnaomics for the treatment of hyperlipidemia and hypertriglyceridemia. It utilizes the company's proprietary GalAhead (muRNA) platform, which involves GalNAc-conjugated siRNA molecules designed to silence two key targets in lipid metabolism: Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Angiopoietin-like 3 (ANGPTL3). By simultaneously inhibiting these targets, STP271G aims to lower both low-density lipoprotein cholesterol (LDL-C) and triglycerides. The drug is designed for subcutaneous administration and leverages GalNAc conjugation for targeted delivery to hepatocytes.
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)ANGPTL3 (Angiopoietin-like protein 3)
Beyond the preview
Go deeper on STP271G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STP271G.